Shares of 20/20 Biolabs (AIDX) jumped 9.6% to $0.51 after the company disclosed that shareholders voted to increase authorized common stock from 50 million to 500 million shares — a tenfold increase clearing the way for future equity issuance. The move gives this tiny AI-powered cancer-diagnostics firm an enormous war chest of unissued shares, raising a blunt question: is the company gearing up to fund real growth, or preparing to dilute its way to survival?
A Sub-$10-Million Company With Giant Ambitions and Deep Losses. AIDX's market cap stands at roughly $6.9 million.
Q2 2026 revenue rose 36.5% to $0.7 million, with its flagship multi-cancer blood test up 47% year-over-year. But net loss for Q2 was $1.5 million, nearly double the prior year's $0.8 million. Revenue is accelerating; losses are accelerating faster.
The Cash Math Explains the Share Expansion. Cash totaled $4.5 million as of June 30, boosted by $6.0 million of Series E preferred stock proceeds. At the current quarterly burn rate, that buys roughly 18 months of runway. The company has a preferred purchase agreement allowing up to $40 million in multiple tranches subject to conditions — but converting preferred stock into common requires available authorized shares. With only about 19.5 million shares outstanding on a fully diluted basis and up to 30,000 additional Series E preferred shares convertible into common , the old 50-million-share ceiling was a binding constraint. The new 500 million ceiling removes it entirely.
Dilution Is Not Theoretical — It Is the Business Model. The company has already filed prospectuses registering up to 15.2 million shares and another 10.1 million shares for resale by existing holders. A new 2026 equity incentive plan reserves 5 million shares plus an automatic annual increase of 7% of shares outstanding , guaranteeing a steadily rising share count. For current holders, every future issuance slices the pie thinner.
Growing Revenue Offers a Narrow Path to Justification. Gross profit rose 87% and gross margin expanded to 41.7% from 30.5% , and the company added 29 new customer accounts including fire departments and occupational health firms. If those contracts scale, future share sales fund genuine expansion rather than just keeping the lights on.
Bottom line: the share authorization is a loaded tool — it can build the company or bury its shareholders. At $0.51 a share, investors are betting management uses the ammunition wisely. History says that's a coin flip for micro-caps burning cash at this rate.